Overview

Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea
Phase:
Phase 4
Details
Lead Sponsor:
Solvay Pharmaceuticals
Treatments:
Progesterone